All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IIIa stage IIIb stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), anti-PD-(L)1 vs. taxanes, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
JAVELIN Lung 200 (all population), 2018 0.90 [0.75; 1.08]
JAVELIN Lung 200 (PDL1 >1%), 2018 0.90 [0.72; 1.12]
OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.78 [0.72 ; 0.85 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 8 23% 4,875 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
0.53 [0.22 ; 1.23 ] CheckMate 017, 2015, CheckMate 078, 2019 2 77% 776 moderate not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
0.69 [0.44 ; 1.07 ] CheckMate 017, 2015, CheckMate 078, 2019 2 46% 776 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
JAVELIN Lung 200 (all population), 2018 1.16 [0.97; 1.39]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.01 [0.80; 1.28]
OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
POPLAR, 2016 0.94 [0.72; 1.23]
0.91 [0.81 ; 1.01 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 8 62% 4,875 moderate not evaluable DORdetailed results OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
9.61 [3.07 ; 30.08 ] OAK (PDL1 TC 1/2/3), 2016 1 0% 107 NA not evaluable objective responses (ORR)detailed results CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
JAVELIN Lung 200 (all population), 2018 1.40 [0.92; 2.13]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.76 [1.08; 2.86]
OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
POPLAR, 2016 0.99 [0.52; 1.91]
1.59 [1.25 ; 2.03 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 8 48% 4,875 moderate serious objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
1.63 [0.19 ; 14.17 ] CheckMate 017, 2015, CheckMate 078, 2019 2 91% 776 moderate not evaluable AE (any grade)detailed results CheckMate 057, 2015 0.31 [0.20; 0.48]
OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.50 [0.26 ; 0.95 ] CheckMate 057, 2015, OAK (all population), 2016, POPLAR, 2016 3 66% 2,019 moderate not evaluable AE (grade 3-4)detailed results CheckMate 057, 2015 0.42 [0.29; 0.59]
OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.50 [0.42 ; 0.59 ] CheckMate 057, 2015, OAK (all population), 2016, POPLAR, 2016 3 0% 2,019 moderate not evaluable AE leading to death (grade 5)detailed results OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
0.80 [0.40 ; 1.57 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.45 [0.24 ; 0.87 ] OAK (all population), 2016, POPLAR, 2016 2 66% 1,464 moderate not evaluable SAE (any grade)detailed results POPLAR, 2016 1.05 [0.64; 1.73]
1.05 [0.64 ; 1.73 ] POPLAR, 2016 1 0% 277 NA not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
OAK (all population), 2016 1.03 [0.80; 1.31]
0.34 [0.03 ; 3.42 ] CheckMate 017, 2015, OAK (all population), 2016 2 93% 1,447 moderate not evaluable STRAE (any grade)detailed results CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
JAVELIN Lung 200 (all population), 2018 0.37 [0.24; 0.57]
0.37 [0.27 ; 0.52 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 30% 2,066 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
0.29 [0.19 ; 0.45 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable TRAE (any grade)detailed results CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 078, 2019 0.35 [0.22; 0.57]
JAVELIN Lung 200 (all population), 2018 0.29 [0.21; 0.42]
OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.29 [0.24 ; 0.35 ] CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 5 0% 2,975 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
JAVELIN Lung 200 (all population), 2018 0.12 [0.08; 0.18]
OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.14 [0.10 ; 0.20 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 6 75% 3,530 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
JAVELIN Lung 200 (all population), 2018 0.19 [0.05; 0.68]
OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.30 [0.13 ; 0.69 ] CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, OAK (all population), 2016, POPLAR, 2016 5 0% 2,975 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 078, 2019 0.66 [0.32; 1.37]
JAVELIN Lung 200 (all population), 2018 0.47 [0.29; 0.77]
POPLAR, 2016 0.07 [0.02; 0.29]
0.35 [0.17 ; 0.71 ] CheckMate 017, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, POPLAR, 2016 4 64% 1,788 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 078, 2019 0.80 [0.33; 1.95]
0.52 [0.16 ; 1.64 ] CheckMate 017, 2015, CheckMate 078, 2019 2 44% 753 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.74 [0.08 ; 7.10 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
1.86 [0.06 ; 55.60 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.65 [0.10 ; 4.29 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
JAVELIN Lung 200 (all population), 2018 0.03 [0.00; 0.44]
0.10 [0.03 ; 0.34 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.72 [0.08 ; 6.15 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 057, 2015 0.15 [0.02; 1.28]
JAVELIN Lung 200 (all population), 2018 0.06 [0.01; 0.49]
0.10 [0.03 ; 0.36 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
1.74 [0.24 ; 12.56 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.23 [0.01; 5.17]
0.40 [0.04 ; 4.62 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.07 [0.00; 1.15]
0.25 [0.05 ; 1.16 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.38 [0.11 ; 1.34 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.04; 5.13]
0.46 [0.04 ; 5.13 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
JAVELIN Lung 200 (all population), 2018 0.09 [0.01; 0.71]
0.18 [0.08 ; 0.39 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.20]
0.02 [0.00 ; 0.09 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Headache TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.44 [0.06 ; 3.38 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 1.86 [0.17; 20.62]
1.86 [0.17 ; 20.62 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
1.00 [0.12 ; 8.54 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
0.81 [0.09 ; 6.95 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
0.91 [0.16 ; 5.34 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 3.74 [0.42; 33.65]
3.74 [0.42 ; 33.65 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 5.64 [0.68; 47.10]
1.93 [0.34 ; 10.91 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 7% 1,806 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
JAVELIN Lung 200 (all population), 2018 0.05 [0.00; 0.78]
0.05 [0.01 ; 0.16 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.09 [0.00; 1.69]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.17 [0.03 ; 1.05 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.55 [0.08 ; 3.90 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.93 [0.02 ; 46.93 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 0.93 [0.13; 6.67]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.46 [0.11 ; 1.95 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.13]
0.02 [0.01 ; 0.05 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.63 [0.05 ; 8.17 ] CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 2 0% 1,313 moderate not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.15 [0.01; 3.09]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.16 [0.03 ; 0.88 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.47 [0.02; 13.95]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.35 [0.05 ; 2.46 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.09 [0.00; 1.68]
0.09 [0.00 ; 1.68 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
JAVELIN Lung 200 (all population), 2018 2.80 [0.29; 27.04]
2.82 [0.77 ; 10.37 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 4 0% 2,066 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
0.72 [0.08 ; 6.19 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
1.08 [0.17 ; 6.66 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 6.60 [0.37; 116.99]
6.60 [0.37 ; 116.99 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.23 [0.01; 5.14]
0.23 [0.01 ; 5.14 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.23 [0.01; 5.17]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.19 [0.02 ; 1.62 ] CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 2 0% 1,313 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
0.35 [0.05 ; 2.48 ] CheckMate 017, 2015, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 3 0% 1,573 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.06; 14.90]
0.93 [0.06 ; 14.90 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Abdominal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.15 [0.01; 3.09]
0.15 [0.01 ; 3.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Alopecia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
OAK (all population), 2016 0.47 [0.02; 14.16]
0.63 [0.05 ; 8.27 ] CheckMate 057, 2015, OAK (all population), 2016 2 0% 1,742 moderate not evaluable Anaemia AE (grade 3-4)detailed results CheckMate 057, 2015 0.38 [0.13; 1.09]
OAK (all population), 2016 0.39 [0.21; 0.73]
0.39 [0.22 ; 0.67 ] CheckMate 057, 2015, OAK (all population), 2016 2 0% 1,742 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 14:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
